Date:2/2/2009

other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

'/>"/>

SOURCE GeneGo, Inc. Copyright©2009 PR Newswire. All rights reserved

2 GOOD

Page: 1 2
Related biology technology :

1. Open Biosystems Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland
2. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
3. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
4. Hovione Buys Pfizers Loughbeg API Facility
5. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
6. Vicenza Hospital Becomes First European Facility to Purchase Its Second CyberKnife System
7. Nikon Instruments Provides Donation to Help Clemson University Start New Core Microscopy Facility
8. BioLife Solutions Credit Facility Increased to $9 Million
9. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
10. Blanchette Rockefeller Neurosciences Institute Hosts First-Ever International Forum on Memory and Memory Disorders and Dedicates New $30 Million Research Facility
11. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.